D-0738-2026 Class III Ongoing

Recalled by Ascend Laboratories, LLC — Bedminster, NJ

FDA drug recall D-0738-2026 was initiated by Ascend Laboratories, LLC on Jul 16, 2026 and is designated Class III. Reason for recall: Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability The recall status is ongoing. Affected quantity: 924 cartons x 12 x 6 x 10 (in blister pack).

Recall details

Product Type
Drugs
Report Date
Aug 5, 2026
Initiation Date
Jul 16, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
924 cartons x 12 x 6 x 10 (in blister pack)

Product description

Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-68.

Reason for recall

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Distribution pattern

USA Nationwide

Code information

Lot: 25141585, Exp. April 30, 2027.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0738-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0738-2026. Report a data issue: hello@regdatalab.com.